MONTE ROSA THERAPEUTICS INC
NASDAQ: GLUE (Monte Rosa Therapeutics, Inc.)
Kemas kini terakhir: 5 jam lalu14.32
-0.06 (-0.42%)
| Penutupan Terdahulu | 14.38 |
| Jumlah Dagangan | 1,080,949 |
| Harga / Jualan (P/S) | 45.96 |
| Harga / Buku (P/B) | 2.50 |
| Julat 52 Minggu |
| Margin Keuntungan | 3.86% |
| Margin Operasi (TTM) | 51.85% |
| EPS Cair (TTM) | 0.120 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7,882.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.21% |
| Nisbah Semasa (MRQ) | 5.61 |
| Aliran Tunai Operasi (OCF TTM) | 34.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 40.54 M |
| Pulangan Atas Aset (ROA TTM) | -0.40% |
| Pulangan Atas Ekuiti (ROE TTM) | 2.88% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Monte Rosa Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.73% |
| % Dimiliki oleh Institusi | 101.33% |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |